ArticleNature communications2017
Predictors of responses to immune checkpoint blockade in advanced melanoma.
Abstract read
In one paragraph
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 146 papers.
0numbers the graph read from it
0cells of the map it votes in
146citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
146 citing papers in PubMed.
- Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.Nature communications · 2024Trial
- Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma.Journal for immunotherapy of cancer · 2022Trial
- A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma.Nature medicine · 2020Trial
- Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma.Clinical and experimental immunology · 2019Trial
- Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study).Technology in cancer research & treatmentTrial
- Interferon-JAK-STAT Axis in Bone Metabolism.Current osteoporosis reports · 2026Review
- Protein-level profiling of TIGIT axis components in human PDAC reveals immune-suppressive expression patterns.Cancer immunology, immunotherapy : CII · 2026Article
- Oncolytic viruses: advanced strategies in cancer therapy.Signal transduction and targeted therapy · 2026Review
- Circulating T-lymphocyte subsets as biomarkers for immune checkpoint inhibitors in solid tumors.Clinical and experimental immunology · 2026Review
- Initiation of Tertiary Lymphoid Structures for Cancer Immunotherapy.Research (Washington, D.C.) · 2026Review
- The evolving role of the immune microenvironment of tumor draining lymph nodes in the development of biomarkers of non-small cell lung cancer.Frontiers in oncology · 2026Review
- Inhibition of TBK1/IKKε mediated RIPK1 phosphorylation sensitizes tumors to immune cell killing.Cell death discovery · 2025Article
- Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity.JHEP reports : innovation in hepatology · 2025Article
- Blood immunomap for prediction of responses to anti-PD-1 immunotherapy in metastatic non-small cell lung cancer.iScience · 2025Article
- Beyond the tumor microenvironment: Orchestrating systemic T‑cell response for next‑generation cancer immunotherapy (Review).International journal of oncology · 2025Review
- A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Impacts of combining PD-L1 inhibitor and radiotherapy on the tumour immune microenvironment in a mouse model of esophageal squamous cell carcinoma.BMC cancer · 2025Article
- NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma.Molecular medicine (Cambridge, Mass.) · 2025Article
- Exploring the relation between TGF-β pathway activity and response to checkpoint inhibition in patients with metastatic melanoma.Clinical and experimental immunology · 2025Article
- Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study.Thoracic cancer · 2025Observational
86 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
50 authors.
N JacquelotINSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
M P RobertiINSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
D P EnotGustave Roussy Cancer Campus, Villejuif, 94800, France.
S RusakiewiczINSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
N TernèsUniversity Paris-Saclay, Kremlin Bicêtre, 94 276, France.
S JegouSaint Antoine Hospital, INSERM ERL 1157-CNRS UMR 7203, Paris, 75005, France.
D M WoodsLaura & Isaac Perlmutter Cancer Center, New York University Medical Center, New York, NY, 10016, USA.
A L SodréLaura & Isaac Perlmutter Cancer Center, New York University Medical Center, New York, NY, 10016, USA.
M HansenCenter for Cancer Immune Therapy, Department of Hematology and Oncology, Copenhagen University Hospital, Herlev, DK-2730, Denmark.
Y MeirowThe Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel.
M Sade-FeldmanThe Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel.
A BurraDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.
S S KwekDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.
C FlamentINSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
M MessaoudeneINSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
C P M DuongINSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
L ChenDepartment of Immunobiology, Yale School of Medicine, 10 Amistad Street, New Haven, CT, 06519, USA.
B S KwonEutilex, Suite# 1401 Daeryung Technotown 17 Gasan Digital 1-ro 25, Geumcheon-gu, Seoul, 08594, Korea.
A C AndersonEvergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
V K KuchrooEvergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
B WeideDepartment of Dermatology, University Medical Center Tübingen, Tübingen, 72076, Germany.
F AubinUniversité de Franche Comté, EA3181, SFR4234, Service de Dermatologie, Centre Hospitalier Universitaire (CHU), Besançon, 25000, France.
C BorgDepartment of Medical Oncology, University Hospital of Besancon, 3 Boulevard Alexander Fleming, Besancon, F-25030, France.
S DalleCentre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Lyon, 69000, France.
O BeatrixCentre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Lyon, 69000, France.
M AyyoubINSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
B BalmeCentre Hospitalier Lyon-Sud, Hospices Civils de Lyon and University Claude Bernard Lyon 1, Lyon, 69000, France.
G TomasicGustave Roussy Cancer Campus, Villejuif, 94800, France.
A M Di GiacomoMedical Oncology and Immunotherapy Division, University Hospital of Siena, Viale Bracci, 14, Siena, 53100, Italy.
M MaioMedical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Instituto Toscano Tumori, Siena, 53100, Italy.
D SchadendorfDepartment of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany & German Cancer Consortium (DKTZ), Heidelberg, D-69120, Germany.
I MeleroDivision of Gene Therapy and Hepatology, Centre for Applied Medical Research, Pamplona, 31008, Spain.
B DrénoDepartment of Onco-dermatology, CIC Biotherapy, INSERM U1232, CHU Nantes, Nantes, 44000, France.
A KhammariDepartment of Onco-dermatology, CIC Biotherapy, INSERM U1232, CHU Nantes, Nantes, 44000, France.
R DummerDepartment of Dermatology, University Hospital Zürich and University of Zürich, Zürich, 8091, Switzerland.
M LevesqueDepartment of Dermatology, University Hospital Zürich and University of Zürich, Zürich, 8091, Switzerland.
Y KoguchiEarle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, 97213, USA.
L FongDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, 94143, USA.
M LotemSharett Institute of Oncology, Hadassah Medical Organization, Jerusalem, 91120, Israel.
M BaniyashThe Lautenberg Center for General and Tumor Immunology, BioMedical Research institute Israel Canada of the Faculty of Medicine, The Hebrew University Hadassah Medical School, Jerusalem, 91120, Israel.
H SchmidtDepartment of Oncology, Aarhus University Hospital, Aarhus, DK-8200, Denmark.
I M SvaneCenter for Cancer Immune Therapy, Department of Hematology and Oncology, Copenhagen University Hospital, Herlev, DK-2730, Denmark.
G KroemerGustave Roussy Cancer Campus, Villejuif, 94800, France.
A MarabelleINSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France.
S MichielsGustave Roussy Cancer Campus, Villejuif, 94800, France.
A CavalcantiGustave Roussy Cancer Campus, Villejuif, 94800, France.
M J SmythImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia.ORCID http://orcid.org/0000-0001-7098-7240
J S WeberLaura & Isaac Perlmutter Cancer Center, New York University Medical Center, New York, NY, 10016, USA.
A M EggermontGustave Roussy Cancer Campus, Villejuif, 94800, France.
L ZitvogelINSERM U1015, Gustave Roussy Cancer Campus, Villejuif, 94800, France. Laurence.ZITVOGEL@gustaveroussy.fr.
Funding
Role of Tim-3 in determining T cell immunityR01CA187975 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ANDERSON, ANA C · 2015 to 2025
$3.9MNCI NIH HHS R01 CA187975
Abstract
Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune related adverse events and increasing use of ICB, predictors of response to CTLA-4 and/or PD-1 blockade represent unmet clinical needs. Using a systems biology-based approach to an assessment of 779 paired blood and tumor markers in 37 stage III MMel patients, we analyzed association between blood immune parameters and the functional immune reactivity of tumor-infiltrating cells after ex vivo exposure to ICB. Based on this assay, we retrospectively observed, in eight cohorts enrolling 190 MMel patients treated with ipilimumab, that PD-L1 expression on peripheral T cells was prognostic on overall and progression-free survival. Moreover, detectable CD137 on circulating CD8
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.